Pazopanib hydrochloride is under clinical development by Novartis and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pazopanib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pazopanib hydrochloride overview
Pazopanib hydrochloride (Votrient, Patorma) is an antineoplastic agent. It is formulated as film coated tablets and tablets for oral administration. It is indicated in adults for the first line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease, and for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS). Votrient is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Pazopanib hydrochloride is under development for the treatment of hormone receptor positive advanced breast cancer, osteosarcoma, Von Hippel-Lindau syndrome, ewing sarcoma, liposarcoma, neuroblastoma, hepatoblastoma, rhabdomyosarcoma, non-rhabdomatous soft tissue sarcoma chondrosarcoma, thyroid cancer, angiosarcoma, salivary gland cancer, recurrent glioblastoma multiforme, glioblastoma multiforme, ovarian cancer, fallopian tube cancer, and peritoneal cancer, metastatic merkel cell carcinoma, metastatic cholangiocarcinoma (adenocarcinoma of intrahepatic).
The drug candidate was under development for the treatment of metastatic renal cell cancer, uterine leiomyosarcomas, bleeding in hereditary haemorrhagic telangiectasia patients, uterine carcinosarcomas, relapsed or refractory multiple myeloma, hepatocellular carcinoma, adenocarcinoma of the prostate, cervical cancer, non-small cell lung cancer, chronic plaque psoriasis, relapsed or refractory acute myeloid leukemia, metastatic colorectal cancer, gastrointestinal stromal tumor (GIST), head and neck cancer squamous cell carcinoma, small cell lung cancer and age related macular degeneration, proximal extrahepatic,distal extrahepatic,gallbladder adenocarcinoma and periampullary bile duct adenocarcinoma).
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Pazopanib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.